Immuno-Onoclogy Summit 2022 Posters

posters

Immuno-Onoclogy Summit 2022 Posters

Check out the latest data on patient-derived organoids for immunotherapy development

Read More

ELRIG 2022 Posters

posters

ELRIG 2022 Posters

Check out the latest data on patient-derived organoids that HUB presented at ELRIG drug discovery meeting in 2022.

Read More

Human liver patient-derived HUB Organoids as a promising tool to study drug-induced liver injury and drug metabolism for improved preclinical toxicology assessment

posters

Human liver patient-derived HUB Organoids as a promising tool to study drug-induced liver injury and drug metabolism for improved preclinical toxicology assessment

Drug toxicology studies are essential for assessing drug safety and represent a pivotal step in the preclinical stages of drug...

Read More

Drug discovery to clinical trials in five years

case study

Drug discovery to clinical trials in five years

Proof-of-concept study highlighting how HUB Organoids® can be used to accelerate your preclinical drug development timeline to just about five...

Read More

De-risk your immuno-oncology drug development with HUB Organoids®

fact sheets

De-risk your immuno-oncology drug development with HUB Organoids®

Immunotherapy has shown substantial success in cancer treatment, however its efficacy is limited to only a subset of patients.

read more

Application of HUB Organoids® in immuno-oncology drug development

fact sheets

Application of HUB Organoids® in immuno-oncology drug development

Immuno-oncology (IO) therapy is a rapidly evolving treatment strategy to combat cancer

read more

HUB Toxicology Organoid Models

fact sheets

HUB Toxicology Organoid Models

Safety-related problems continue to be one of them major causes of drug attrition in preclinical and clinical development. Preclinical safety...

read more

Patient-derived organoids as a model for treatment diagnosis in Cystic Fibrosis – combinatory treatment with read-through agent, correctors and potentiator on rare mutations

posters

Patient-derived organoids as a model for treatment diagnosis in Cystic Fibrosis – combinatory treatment with read-through agent, correctors and potentiator on rare mutations

Cystic fibrosis (CF) patient prognosis has recently improved due to the development of new, more effective treatments and better combination...

Read More

Imagine reducing the time to identify a drug that shows results in the clinic to five years: this proof-of-concept study shows it is possible now

news and insights

Imagine reducing the time to identify a drug that shows results in the clinic to five years: this proof-of-concept study shows it is possible now

The study identifies the first clinical candidate developed using HUB Organoids® and high-content screening that inhibits tumor growth and metastasis...

read more

License HUB Organoid Technology

fact sheets

License HUB Organoid Technology

HUB Organoid Technology represents a breakthrough in stem cell research and has allowed to gain better understanding in fields like...

read more

Patient in the lab: predicting clinical responses using patient-derived organoid screening

posters

Patient in the lab: predicting clinical responses using patient-derived organoid screening

Adult epithelial stem cell-derived organoids (HUB Organoids™) are proving to be a major breakthrough in preclinical models. HUB Organoids are...

read more

Patient-derived organoids predict clinical response: a patient in the lab

posters

Patient-derived organoids predict clinical response: a patient in the lab

Colorectal cancer (CRC) is the third leading cause of cancer and cancer-related death. A large fraction of the CRC patients...

read more

Application of HUB Organoids® to Immunotherapy development

posters

Application of HUB Organoids® to Immunotherapy development

Poster P03: Autologous organoid and T cell co-cultures as a powerful personalized platform for Immunotherapy development

read more

HUB Organoid biobank

info sheets

HUB Organoid biobank

A vast collection of established patient-derived models. The HUB Organoid Biobank includes more than a thousand of established organoid models...

read more

MIMETAS Expands Adult Stem Cell Organoid License to All Organs

news and insights

MIMETAS Expands Adult Stem Cell Organoid License to All Organs

Leiden, The Netherlands, May 3, 2022 – MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today that it has...

read more

First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer

news and insights

First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer

San Diego, California, April 28, 2022 – Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of...

read more

Exclusive interview with Dr Carla Verissimo

news and insights

Exclusive interview with Dr Carla Verissimo

Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview...

read more

New PERSIST-SEQ program launched

news and insights

New PERSIST-SEQ program launched

2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial...

read more

Link revealed between HBV infection and liver cancer

paper

Link revealed between HBV infection and liver cancer

HUB Organoids® derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events...

read more

New service partnership

news and insights

New service partnership

VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for...

read more

HUB Toxicology Organoid Models

fact sheets

HUB Toxicology Organoid Models

Safety-related problems continue to be one of the major causes of drug attrition in preclinical and clinical development. Preclinical safety...

read more

CF models for drug development

paper

CF models for drug development

HUB Organoids® supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids advance...

read more

Test epithelial barrier function

paper

Test epithelial barrier function

Discover the development of a new model to assess drug safety, absorption, methabolism, transport, and permeability. Compromised intestinal barrier function...

read more

HUB at Innovation Parade

news and insights

HUB at Innovation Parade

HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the Innovation Parade, an online event organized by the Embassy of the Kingdom...

read more

HUB and Yamaha for IVD

news and insights

HUB and Yamaha for IVD

April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today continuation of their collaboration...

read more

Next-gen diagnostics

news and insights

Next-gen diagnostics

Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced today that they have signed a Memorandum of Understanding (MoU) to...

read more

Ovarian cancer organoids

news and insights

Ovarian cancer organoids

Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous...

read more

EUROTOX 2021 | Poster 391

posters

EUROTOX 2021 | Poster 391

Discover how to reduce costly animal experiments and obtain a quick indication of your drug safety with Merel Derksen. Poster 391: Intestinal organoids as in...

read more

EUROTOX 2021 | Poster 553

posters

EUROTOX 2021 | Poster 553

Dr. Pourfarzad presents data on the use of HUB Organoids as advanced modes to investigate ADME and safety. Poster 553: HUB Organoids™ improve preclinical toxicology,...

read more

HUB Immuno-Oncology Organoid Models

fact sheets

HUB Immuno-Oncology Organoid Models

Advances in immunotherapy have revolutionized cancer treatment over the past few years – reflecting the importance of the interaction between...

read more

Cystic Fibrosis Organoid Models

fact sheets

Cystic Fibrosis Organoid Models

Cystic fibrosis (CF) is a genetic disease that is caused by mutations of the gene encoding for Cystic Fibrosis Transmembrane...

read more

Understanding gut’s hormones

news and insights

Understanding gut’s hormones

Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species...

read more

SARS-CoV-2 infects gut cells

news and insights

SARS-CoV-2 infects gut cells

Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have...

read more

A message from our CEO

news and insights

A message from our CEO

Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak....

read more

Organoids for genetic disorders

news and insights

Organoids for genetic disorders

Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest...

read more

HUB on Financial Times

news and insights

HUB on Financial Times

On December 10, 2019 the Financial Times featured HUB Organoids™ in an article titled “Organoid innovation offers potential for cancer...

read more

Patient in the lab®: downscaling patient-derived organoid screening

ON-DEMAND PRESENTATION

Patient in the lab®: downscaling patient-derived organoid screening

Drug discovery and development is a lengthy process, often starting with the identification of new drug targets – based on...

read more

2021 Organoids are us

ON-DEMAND PRESENTATION

2021 Organoids are us

New online presentation available on the use of HUB Organoids™ as a revolutionary approach to disease modeling, drug screening, and...

read more

Model human diseases and select treatment

ON-DEMAND PRESENTATION

Model human diseases and select treatment

Our CEO Dr. Rob Vries discusses how HUB Organoids help modelling human disease and select best treatement options. Classic in...

read more

PDX organoids in drug development

news and insights

PDX organoids in drug development

San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform...

read more

Organoids-on-a-chip

news and insights

Organoids-on-a-chip

Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to...

read more

Epistem license HUB Technology

news and insights

Epistem license HUB Technology

Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of...

read more

Model inflammation in a dish

ON-DEMAND PRESENTATION

Model inflammation in a dish

Watch Dr. Sylvia Boj discussing how HUB Organoids accelerate the development of new therapeutics for inflammatory diseases. The lack of...

read more

Accelerating oncology drug discovery with HUB Organoids

white papers

Accelerating oncology drug discovery with HUB Organoids

Oncology drug development is especially risky with only 5% of new compounds reaching market approval. The lack of patient-relevant, early-stage...

read more

HUB tumor organoid models

fact sheets

HUB tumor organoid models

HUB Organoids™ are unique patient-derived in vitro models developed directly from patient biopsies or resections.

read more

HUB Organoids: a patient in the lab

application notes

HUB Organoids: a patient in the lab

HUB was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and...

read more

HUB PDOs now at CrownBio

news and insights

HUB PDOs now at CrownBio

San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht...

read more

Personalized Health Basel

ON-DEMAND PRESENTATION

Personalized Health Basel

Dr. Vries joins the monthly seminar series organized by the Personalized Health Basel (PHB) initiative. Personalized medicine holds great promise for the future of patient treatment,...

read more

New partner: CrownBio

news and insights

New partner: CrownBio

March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation, the parent company, of Crown Bioscience, entered into a...

read more

Organoids for infectious disease

ON-DEMAND PRESENTATION

Organoids for infectious disease

HUB Organoids as models for precision medicine, in vitro diagnostics, and infectious disease. During this virtual mini-symposium co-hosted with our...

read more

New partner: Yamaha Motor

news and insights

New partner: Yamaha Motor

February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their collaboration to provide...

read more

X

Have any questions?

contact us